Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Staggered Dose-Escalating Phase IIb Study of the Safety and Efficacy of Istaroxime Over 24 Hours at Three Doses in Acute Decompensated Heart Failure Patients (The IGNITE Trial).
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Istaroxime (Primary)
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Acronyms IGNITE
- Sponsors Debiopharm
- 05 May 2017 This trial has been completed in France (End date:2009-09-04) as per European Clinical Trials Database.
- 04 Jul 2012 Actual end date 3 Sep 2009 added as reported by EudraCT.
- 04 Nov 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.